Practice Question # 924.
Time limit: 0
0 of 1 questions completed
You have already completed the quiz before. Hence you can not start it again.
Quiz is loading...
You must sign in or sign up to start the quiz.
You have to finish following quiz, to start this quiz:
0 of 1 questions answered correctly
Time has elapsed
You have reached 0 of 0 points, (0)
Hydromorphone Pharama Review:
Moderate to severe pain
Binds with opioid receptors in the CNS, altering perception of and emotional response to pain. Also suppresses the cough reflex by direct action on the cough center in the medulla.
- CNS: sedation, somnolence, clouded sensorium, dizziness, euphoria, light-headedness, insomnia, headache, pain CV: hypotension, flushing, bradycardia, edema
- EENT: blurred vision, diplopia, nystagmus
- GI: nausea, vomiting, constipation, diarrhea, ileus, dry mouth
- Respiratory: respiratory depression, bronchospasm
Reassess patient’s level of pain at least 15 and 30 minutes after administration. For better effect, give drug before patient has intense pain. Discontinue all other extended-release opioids before giving extended-release form of hydromorphone. Monitor respiratory and circulatory status and bowel function. Keep opioid antagonist (naloxone) available. Don’t use extended-release form within 14 days of stopping MAO inhibitor. Don’t confuse hydromorphone with morphine or oxymorphone or Dilaudid with Dilantin.